JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189
versus placebo in participants with moderately to severely active systemic lupus
erythematosus (SLE) while receiving standard of care (SOC) treatment.